Removal of lepirudin, a recombinant hirudin, by hemodialysis, hemofiltration, or plasmapheresis

被引:19
作者
Willey, ML
de Denus, S
Spinler, SA
机构
[1] Univ Sci Philadelphia, Philadelphia Coll Pharm, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Med, Cardiovasc Sect, Philadelphia, PA 19104 USA
来源
PHARMACOTHERAPY | 2002年 / 22卷 / 04期
关键词
D O I
10.1592/phco.22.7.492.33671
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Lepirudin (recombinant hirudin), a direct thrombin inhibitor, is an effective alternative method of anticoagulation in patients with heparin-induced thrombocytopenia. However, because it is eliminated by the kidneys, the half-life of lepirudin may be substantially prolonged in patients with renal failure. Patients undergoing hemodialysis must be closely monitored, and therapy must be individualized based on each patient's ability to clear the drug. Current literature on the removal of lepirudin by dialysis or plasmapheresis is limited, but available data suggest that lepirudin can be removed with these methods. The ability of filtration systems to remove lepirudin from the blood is highly dependent on the membrane material used in the system. Understanding the effects of hemodialysis, hemofiltration, and plasmapheresis on lepirudin levels is important, especially since no antidote is available to treat elevated serum lepirudin concentrations.
引用
收藏
页码:492 / 499
页数:8
相关论文
共 19 条
[1]   Treatment of hirudin overdosage in a patient with chronic renal failure [J].
Bauersachs, RM ;
Lindhoff-Last, E ;
Ehrly, AM ;
Betz, C ;
Geiger, H ;
Hauser, IA .
THROMBOSIS AND HAEMOSTASIS, 1999, 81 (02) :323-324
[2]  
*BERL LAB, 2001, REFL LEP PACK INS
[3]   R-hirudin as anticoagulant in regular hemodialysis therapy: Finding of therapeutic r-hirudin blood plasma concentrations and respective dosages [J].
Bucha, E ;
Nowak, G ;
Czerwinski, R ;
Thieler, H .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 1999, 5 (03) :164-170
[4]   In vitro study of r-hirudin permeability through membranes of different haemodialysers [J].
Bucha, E ;
Kreml, R ;
Nowak, G .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (12) :2922-2926
[5]   Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis [J].
Clark, WR ;
Hamburger, RJ ;
Lysaght, MJ .
KIDNEY INTERNATIONAL, 1999, 56 (06) :2005-2015
[6]   Clinical monitoring of direct thrombin inhibitors using the ecarin clotting time [J].
de Denus, S ;
Spinler, SA .
PHARMACOTHERAPY, 2002, 22 (04) :433-435
[7]  
DIRCKX JH, STEDMANS CONCISE MED
[8]   Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis [J].
Fischer, KG ;
van de Loo, A ;
Böhler, J .
KIDNEY INTERNATIONAL, 1999, 56 :S46-S50
[9]   Current concepts: Continuous hemofiltration in the treatment of acute renal failure [J].
Forni, LG ;
Hilton, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (18) :1303-1309
[10]   Hirudin elimination by hemofiltration:: A comparative in vitro study of different membranes [J].
Frank, RD ;
Farber, H ;
Stefanidis, I ;
Lanzmich, R ;
Kierdorf, HP .
KIDNEY INTERNATIONAL, 1999, 56 :S41-S45